


Olsen, C.<sup>1</sup>; Clemens, P.R.<sup>2</sup>; Damsker, J.<sup>3</sup>; Conklin, L.<sup>3</sup>; Smith, A.<sup>4</sup>; Morgenroth, L.<sup>4</sup>; McCall, J.<sup>3</sup>; Guglieri, M.<sup>5</sup>; Head, R.<sup>1</sup>; Athanasiou, D.<sup>6</sup>; Vroom, E.<sup>6</sup>; Morgenroth, L.<sup>4</sup>; Haberlova, J.<sup>7</sup>; Demotes-Mainard, J.<sup>8</sup>; Crow, R.<sup>5</sup>; Klager, S.<sup>8</sup>; Arrieta, A.<sup>4</sup>; Jusko, W.<sup>9</sup>; Schwartz, B.<sup>10</sup>; Mengle-Gaw, L.<sup>10</sup>; Jaros, M.<sup>11</sup>; Shale, P.<sup>11</sup>; Hoffman, E.P.<sup>3</sup>

<sup>1</sup>Ceratum, UK; <sup>2</sup>University Pittsburgh USA and CINRG network; <sup>3</sup>ReveraGen BioPharma, UK/USA; <sup>4</sup>TRiNDS LLC USA; <sup>5</sup>John Walton Muscular Dystrophy Research Centre, Newcastle University, UK; <sup>6</sup>United Parent Project Muscular Dystrophy, Netherlands; <sup>7</sup>Fakultni Nemocnice v Motole; Czech Republic; <sup>8</sup>ECRIN, France; <sup>9</sup>State University of New York-Buffalo USA; <sup>10</sup>The Camden Group LLC USA <sup>11</sup>Summit Analytical USA

## VISION-DMD is a collaborative project undertaking Phase 2 Clinical Trials of Vamorolone - an Innovative Steroid-like Intervention for Duchenne Muscular Dystrophy.

### Duchenne Muscular Dystrophy

- 1:5000 male births worldwide
- Onset is usually between 2 and 6 years of age
- Caused by mutations in the dystrophin gene
- Progressive muscle weakness and wasting
- Early death from cardiorespiratory failure
- Treatments generally palliative in nature



### Glucocorticoids – Standard of Care for DMD


- ❖ Prednisone and deflazacort are the only treatment option for DMD that is independent of mutation type
- ❖ Mechanism of action is as an anti-inflammatory
- ❖ Glucocorticoids improve muscle strength, prolong ambulation, delay respiratory and orthopaedic complications and very likely prolong survival

## Glucocorticoids show severe safety concerns: Multiple side effects detract from patient quality of life, lead to variation in practice

### Vamorolone: A first-in-class dissociative steroid

- ✓ An innovative steroid-like drug designed to retain or improve glucocorticoid anti-inflammatory efficacy
- ✓ Mineralocorticoid receptor antagonist – additional efficacy
- ✓ Reduced side effects
- ✓ Membrane stabilizing activity
- ✓ Better safety profile enables higher dosing

Comparison of the experimentally determined crystal structures of vamorolone and prednisone.



Structure overlay of Vamorolone (Vam, red) and Prednisone (Pred, blue).

### Phase 1 clinical trial in adult volunteers


- Pharmacokinetic (PK) data in single and multiple ascending doses up to 20 mg/kg/day for 14 days: strong adherence to dose linearity and dose proportionality
- No drug accumulation observed, consistent with short half-life
- No adverse events precluding further escalations in dosing observed
- Safety pharmacodynamics (PD) biomarker studies showed loss of insulin resistance, loss of bone safety concerns, increased window for adrenal suppression
- Published: Hoffman et al. 2018; *Steroids*

### Phase 2a in 4 to <7 years DMD boys

**Phase 2a: Multiple ascending dose, 2 weeks on, 2 weeks washout - complete**  
**Phase 2a extension: 6 months at same dose - complete**  
**Phase 2a Long-term extension: 2 years with dose escalations permitted - ongoing**

- 48 patients recruited at 11 Cooperative International Neuromuscular Research (CINRG) sites: USA (5), Canada (1), UK (1), Australia (2), Israel (1), Sweden (1)
- Four dose groups: 0.25, 0.75, 2.0, 6.0 mg/kg/day (12 patients/dose group)
- All doses well tolerated; PK and metabolites in DMD children similar to healthy adults (Phase 1)
- Considered safe to 6.0 mg/kg/day (~10x typical prednisone dose)
- High retention of patients through sequential studies (95% in LTE)

Dose Level Group-	No. Subjects/ Group	Vamorolone Dose
1	12	0.25 mg/Kg
2	12	0.75 mg/Kg
3	12	2.0 mg/Kg
4	12	6.0 mg/Kg



- PK run on initial 6 boys in 0.25 mg/kg/day
- PK in DMD children similar to fasted adults
- Increased bioavailability with milk likely offset by faster metabolism in children

\*Bill Jusko, SUNY Buffalo

### Phase 2b study - Recruiting May 2018

- Randomised, Double-blind, Parallel Group, placebo and active controlled study
- >30 sites: EU (18), USA (9), Canada (4), Australia (2), Israel (1)
- 120 steroid naïve genetically confirmed DMD boys 4-<7 years
- 24-week placebo and active controlled treatment period 1 followed by 24 week extension
- Primary efficacy outcome: time to stand
- Primary safety outcome: change in body mass index
- Exploratory biomarkers and muscle MRI

#### Primary Objectives

1. To compare the efficacy of vamorolone administered orally at daily doses of 2 mg/kg and 6 mg/kg over a 24-week treatment period vs. placebo in ambulant boys ages 4 to <7 years with DMD
2. To evaluate the safety and tolerability of vamorolone administered orally at daily doses of 2 mg/kg and 6 mg/kg in ambulant boys ages 4 to <7 years with DMD.

#### Secondary Objectives

1. To compare the safety of vamorolone over a 24-week treatment period vs. prednisone
2. To compare the efficacy of vamorolone over a 24-week treatment period vs. prednisone
3. To compare the efficacy of 2 mg/kg vamorolone vs. 6 mg/kg vamorolone over a 24 week treatment period
4. To compare the efficacy of 2 mg/kg vamorolone vs. 6 mg/kg vamorolone over a 48 week treatment period vs. untreated DMD historical controls
5. To compare the efficacy of 2 mg/kg vamorolone vs. 6 mg/kg vamorolone over a 48 week treatment period vs. prednisone treated DMD historical controls
6. To evaluate the population pharmacokinetics (PK) of vamorolone at daily doses of 2 mg/kg and 6 mg/kg in ambulant boys ages 4 to <7 years with DMD

Group	No Subjects/ group	Treatment period 1	Treatment period 2
1	30	Vamorolone, 2.0 mg/kg/day →	Vamorolone, 2.0 mg/kg/day
2	30	Vamorolone, 6.0 mg/kg/day →	Vamorolone, 6.0 mg/kg/day
3	15	Prednisone, 0.75 mg/kg/day →	Vamorolone, 2.0 mg/kg/day
4	15	Prednisone, 0.75 mg/kg/day →	Vamorolone, 6.0 mg/kg/day
5	15	Placebo →	Vamorolone, 2.0 mg/kg/day
6	15	Placebo →	Vamorolone, 6.0 mg/kg/day

### VISION-DMD International Consortium



### Vamorolone Development through Grants & Venture Philanthropy



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 667078; Phase 2a has US funding from NIH NIAMS U34AR068616 (Paula Clemens, University of Pittsburgh) and NIH NINDS R44NS095423 (Eric Hoffman, ReveraGen; Paula Clemens, University of Pittsburgh)

